Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, Thailand.
Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Pharmacokinetic Research Unit, Naresuan University, Phitsanulok, Thailand.
Clin Drug Investig. 2020 May;40(5):395-420. doi: 10.1007/s40261-020-00901-x.
The levonorgestrel oral emergency contraceptive is well tolerated and effective, however its use is still limited, mainly due to safety concerns.
This systematic review and meta-analysis aimed to summarize current evidence regarding the adverse events, and their prevalence, reported during the use of oral levonorgestrel emergency contraceptives.
Four electronic databases and the US FDA Adverse Event Reporting System (FAERS) Public Dashboard were searched. Studies that reported or investigated safety outcomes or adverse reactions during the use of levonorgestrel as an emergency oral contraceptive were included. Data on study design, demographics of levonorgestrel and the control cohort, and reported adverse effects were extracted.
A total of 47 articles were included in this systematic review, from which it was shown that most of the adverse reactions were common and not serious. Uncommon adverse reactions identified included anorexia, ectopic pregnancy, exanthema, chloasma, miscarriage, and weight gain. Multiple serious adverse events, including convulsion, ectopic pregnancy, febrile neutropenia, stroke, abdominal hernia, anaphylaxis, cancer, ovarian cyst rupture, serious infections, and suicidal ideation, were reported. In addition, the prevalence of adverse events after a levonorgestrel 0.75 mg two-dose regimen and a levonorgestrel 1.5 mg single-dose regimen were not statistically different (p > 0.05).
The most common adverse effects of levonorgestrel were not serious. This systematic review shows that data regarding the adverse reactions of repeated use of levonorgestrel are scarce. Studies on the multiple uses of levonorgestrel emergency contraception are still required to ensure its safety.
左炔诺孕酮口服紧急避孕药具有良好的耐受性和有效性,但其使用仍然受限,主要是由于安全性方面的担忧。
本系统评价和荟萃分析旨在总结目前关于使用左炔诺孕酮口服紧急避孕药时报告的不良事件及其流行率的证据。
检索了四个电子数据库和美国 FDA 不良事件报告系统(FAERS)公共数据看板。纳入报告或调查使用左炔诺孕酮作为紧急口服避孕药时安全性结果或不良反应的研究。提取研究设计、左炔诺孕酮和对照组的人口统计学数据以及报告的不良反应数据。
本系统评价共纳入 47 篇文章,结果表明大多数不良反应常见但不严重。罕见的不良反应包括厌食、宫外孕、皮疹、妊娠斑、流产和体重增加。还报告了多种严重不良事件,包括癫痫发作、宫外孕、发热性中性粒细胞减少症、中风、腹疝、过敏反应、癌症、卵巢囊肿破裂、严重感染和自杀意念。此外,左炔诺孕酮 0.75mg 两剂方案和左炔诺孕酮 1.5mg 单剂方案后不良事件的发生率无统计学差异(p>0.05)。
左炔诺孕酮最常见的不良反应不严重。本系统评价表明,关于重复使用左炔诺孕酮的不良反应数据稀缺。仍需要研究左炔诺孕酮紧急避孕的多次使用,以确保其安全性。